[{"id":"53e5e5c1-1571-4242-aa49-3239a2077780","acronym":"GEMSTONE-303","url":"https://clinicaltrials.gov/study/NCT03802591","created_at":"2021-01-18T18:47:48.618Z","updated_at":"2024-07-02T16:35:27.807Z","phase":"Phase 3","brief_title":"A Study of CS1001 in Subjects With Gastric Adenocarcinoma or Gastro-Esophageal Junction Adenocarcinoma","source_id_and_acronym":"NCT03802591 - GEMSTONE-303","lead_sponsor":"CStone Pharmaceuticals","biomarkers":" PD-L1","pipe":" | ","alterations":" PD-L1 expression","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e capecitabine • oxaliplatin • Cejemly (sugemalimab)"],"overall_status":"Completed","enrollment":" Enrollment 479","initiation":"Initiation: 03/28/2019","start_date":" 03/28/2019","primary_txt":" Primary completion: 07/09/2023","primary_completion_date":" 07/09/2023","study_txt":" Completion: 09/22/2023","study_completion_date":" 09/22/2023","last_update_posted":"2023-11-29"},{"id":"0ff2ef02-f3f0-4681-b3ce-d92b732fc264","acronym":"GEMSTONE-304","url":"https://clinicaltrials.gov/study/NCT04187352","created_at":"2021-01-18T20:24:42.341Z","updated_at":"2024-07-02T16:35:28.232Z","phase":"Phase 3","brief_title":"A Study of CS1001 in Subjects With Esophageal Squamous Cell Carcinoma","source_id_and_acronym":"NCT04187352 - GEMSTONE-304","lead_sponsor":"CStone Pharmaceuticals","biomarkers":" PD-L1","pipe":" | ","alterations":" PD-L1 expression","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cisplatin • 5-fluorouracil • Cejemly (sugemalimab)"],"overall_status":"Completed","enrollment":" Enrollment 540","initiation":"Initiation: 12/19/2019","start_date":" 12/19/2019","primary_txt":" Primary completion: 10/07/2022","primary_completion_date":" 10/07/2022","study_txt":" Completion: 10/07/2022","study_completion_date":" 10/07/2022","last_update_posted":"2023-11-24"},{"id":"5d643950-2bd3-459b-9947-9ffdee8a0b7d","acronym":"","url":"https://clinicaltrials.gov/study/NCT06097962","created_at":"2023-10-24T15:13:56.310Z","updated_at":"2024-07-02T16:35:31.830Z","phase":"Phase 1","brief_title":"Safety and Efficacy of NK510 to Treat NSCLC","source_id_and_acronym":"NCT06097962","lead_sponsor":"Base Therapeutics (Shanghai) Co., Ltd.","biomarkers":" PD-L1","pipe":" | ","alterations":" PD-L1 expression","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Tecentriq (atezolizumab) • Tevimbra (tislelizumab-jsgr) • Cejemly (sugemalimab)"],"overall_status":"Recruiting","enrollment":" Enrollment 9","initiation":"Initiation: 07/01/2023","start_date":" 07/01/2023","primary_txt":" Primary completion: 07/01/2024","primary_completion_date":" 07/01/2024","study_txt":" Completion: 07/01/2024","study_completion_date":" 07/01/2024","last_update_posted":"2023-10-25"},{"id":"312b4cba-7ef8-463c-b7a6-9647c77dbabf","acronym":"","url":"https://clinicaltrials.gov/study/NCT06031597","created_at":"2023-09-11T16:10:34.888Z","updated_at":"2024-07-02T16:35:37.406Z","phase":"Phase 3","brief_title":"Radiotherapy Combined With ICIs as Treatment for LA-NSCLC After Failing Induction Immunochemotherapy","source_id_and_acronym":"NCT06031597","lead_sponsor":"Zhejiang Cancer Hospital","biomarkers":" EGFR • ALK • ROS1","pipe":"","alterations":" ","tags":["EGFR • ALK • ROS1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • Opdivo (nivolumab) • cisplatin • Tecentriq (atezolizumab) • Imfinzi (durvalumab) • Tyvyt (sintilimab) • AiRuiKa (camrelizumab) • Tevimbra (tislelizumab-jsgr) • Cejemly (sugemalimab)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 105","initiation":"Initiation: 09/15/2023","start_date":" 09/15/2023","primary_txt":" Primary completion: 12/31/2025","primary_completion_date":" 12/31/2025","study_txt":" Completion: 12/31/2025","study_completion_date":" 12/31/2025","last_update_posted":"2023-09-12"},{"id":"51207963-8174-43df-80e2-60d9fb75d7b0","acronym":"GEMSTONE302","url":"https://clinicaltrials.gov/study/NCT03789604","created_at":"2021-01-17T17:24:55.161Z","updated_at":"2024-07-02T16:35:41.215Z","phase":"Phase 3","brief_title":"A Study of CS1001 in Subjects With Stage IV Non-Small Cell Lung Cancer","source_id_and_acronym":"NCT03789604 - GEMSTONE302","lead_sponsor":"CStone Pharmaceuticals","biomarkers":" PD-L1","pipe":" | ","alterations":" PD-L1 expression","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e carboplatin • paclitaxel • Cejemly (sugemalimab)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 479","initiation":"Initiation: 12/13/2018","start_date":" 12/13/2018","primary_txt":" Primary completion: 05/15/2023","primary_completion_date":" 05/15/2023","study_txt":" Completion: 06/30/2025","study_completion_date":" 06/30/2025","last_update_posted":"2023-08-02"},{"id":"8618c3fa-4468-4945-aa54-0b000144497e","acronym":"","url":"https://clinicaltrials.gov/study/NCT04194801","created_at":"2023-02-06T18:00:21.094Z","updated_at":"2024-07-02T16:35:56.405Z","phase":"Phase 1/2","brief_title":"A Phase Ib/II Study of Fisogatinib(BLU-554) in Subjects With Hepatocellular Carcinoma","source_id_and_acronym":"NCT04194801","lead_sponsor":"CStone Pharmaceuticals","biomarkers":" PD-L1","pipe":"","alterations":" ","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Cejemly (sugemalimab) • fisogatinib (BLU-554)"],"overall_status":"Completed","enrollment":" Enrollment 26","initiation":"Initiation: 12/16/2019","start_date":" 12/16/2019","primary_txt":" Primary completion: 10/20/2021","primary_completion_date":" 10/20/2021","study_txt":" Completion: 10/20/2021","study_completion_date":" 10/20/2021","last_update_posted":"2023-02-06"},{"id":"8c19931a-7080-4fe7-8a87-971b5f136150","acronym":"","url":"https://clinicaltrials.gov/study/NCT04200404","created_at":"2021-01-18T20:28:08.282Z","updated_at":"2025-02-25T17:24:26.990Z","phase":"Phase 1/2","brief_title":"A Study of CS1001 in Combination With Regorafenib in Patients With Advanced or Refractory Solid Tumors","source_id_and_acronym":"NCT04200404","lead_sponsor":"CStone Pharmaceuticals","biomarkers":" PD-L1","pipe":" | ","alterations":" PD-L1 expression","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Stivarga (regorafenib) • Cejemly (sugemalimab)"],"overall_status":"Completed","enrollment":" Enrollment 19","initiation":"Initiation: 12/13/2019","start_date":" 12/13/2019","primary_txt":" Primary completion: 05/13/2021","primary_completion_date":" 05/13/2021","study_txt":" Completion: 08/18/2021","study_completion_date":" 08/18/2021","last_update_posted":"2022-05-06"}]